Overview
Mitochondrial DNA depletion syndrome, myopathic form (also known as MDS, myopathic form or mitochondrial DNA depletion syndrome 2, myopathic type) is a rare, severe genetic disorder characterized by a marked reduction in mitochondrial DNA (mtDNA) copy number primarily affecting skeletal muscle. This leads to impaired mitochondrial respiratory chain function and progressive muscle weakness. The condition predominantly affects the muscular system, though other organs may also be involved to varying degrees. It is caused by pathogenic variants in genes essential for mitochondrial DNA maintenance, most commonly TK2 (thymidine kinase 2), which encodes an enzyme critical for mitochondrial nucleotide metabolism. The myopathic form typically presents in infancy or early childhood with progressive muscle weakness (myopathy), hypotonia (reduced muscle tone), difficulty feeding, and motor regression — meaning children may lose previously acquired motor skills such as walking or sitting. Affected individuals often develop respiratory insufficiency due to weakness of the breathing muscles, which can be life-threatening. Elevated serum creatine kinase levels and ragged red fibers on muscle biopsy are characteristic findings. Some patients may also develop mild involvement of other organs, but the predominant clinical picture is skeletal muscle disease. Currently, there is no definitive cure for this condition. Management is primarily supportive and includes respiratory support (including mechanical ventilation when needed), physical therapy, nutritional support, and monitoring for complications. Deoxynucleoside substrate therapy (specifically oral deoxynucleosides such as deoxythymidine and deoxycytidine) has shown promise in clinical studies for TK2-related myopathic MDS, with some patients demonstrating stabilization or improvement in motor and respiratory function. Early diagnosis and intervention are important for optimizing outcomes.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Mitochondrial DNA depletion syndrome, myopathic form.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Mitochondrial DNA depletion syndrome, myopathic form at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Mitochondrial DNA depletion syndrome, myopathic form.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mitochondrial DNA depletion syndrome, myopathic form.
Community
No community posts yet. Be the first to share your experience with Mitochondrial DNA depletion syndrome, myopathic form.
Start the conversation →Latest news about Mitochondrial DNA depletion syndrome, myopathic form
No recent news articles for Mitochondrial DNA depletion syndrome, myopathic form.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Mitochondrial DNA depletion syndrome, myopathic form
What is Mitochondrial DNA depletion syndrome, myopathic form?
Mitochondrial DNA depletion syndrome, myopathic form (also known as MDS, myopathic form or mitochondrial DNA depletion syndrome 2, myopathic type) is a rare, severe genetic disorder characterized by a marked reduction in mitochondrial DNA (mtDNA) copy number primarily affecting skeletal muscle. This leads to impaired mitochondrial respiratory chain function and progressive muscle weakness. The condition predominantly affects the muscular system, though other organs may also be involved to varying degrees. It is caused by pathogenic variants in genes essential for mitochondrial DNA maintenance,
How is Mitochondrial DNA depletion syndrome, myopathic form inherited?
Mitochondrial DNA depletion syndrome, myopathic form follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Mitochondrial DNA depletion syndrome, myopathic form typically begin?
Typical onset of Mitochondrial DNA depletion syndrome, myopathic form is infantile. Age of onset can vary across affected individuals.